A drug developed with the help of artificial intelligence, originally intended to treat a rare and serious lung condition, may carry an unexpected bonus: it appears to slow some of the biological processes linked to aging, according to early data released by the company behind it.
The drug, known as rentosertib, was created using AI tools that helped researchers identify a promising molecule far faster than traditional drug discovery methods typically allow. While it was designed to address a specific rare disease affecting the lungs, preliminary results suggest the compound may also reduce certain cellular and molecular signs that scientists associate with aging.
Researchers caution that the findings are still preliminary. The data come from early-stage testing, and much more research will be needed before anyone can say whether the drug truly has anti-aging effects in humans, or whether it could ever be approved for that purpose. Still, the results have generated excitement in the fast-growing field of longevity science, where scientists are increasingly using artificial intelligence to search for compounds that might delay the effects of aging rather than simply treat individual diseases.
For now, rentosertib remains focused on its original target: the rare lung disease for which it was developed. But its possible secondary effects have caught the attention of scientists watching how AI is reshaping drug discovery.
To read the full report, visit the original article at The New York Times.
Source: Early Data Indicates an A.I.-Generated Drug Could Slow Aging (rss.nytimes.com). English version produced with AI assistance.
Image: plasticrevolver, BY-SA 2.0 (via Openverse).